Workflow
Steris (STE) Reports Q3 Earnings: What Key Metrics Have to Say
STESTERIS(STE) ZACKS·2025-02-06 00:36

Core Insights - Steris reported revenue of 1.37billionforthequarterendedDecember2024,adecreaseof1.81.37 billion for the quarter ended December 2024, a decrease of 1.8% year-over-year, with EPS at 2.32 compared to 2.22inthesamequarterlastyear[1]TherevenuefellshortoftheZacksConsensusEstimateof2.22 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of 1.38 billion, resulting in a surprise of -0.67%, while EPS met the consensus estimate [1] Financial Performance - Healthcare revenues were 976.04million,belowtheaverageestimateof976.04 million, below the average estimate of 983.64 million, reflecting a year-over-year increase of 6.5% [4] - Healthcare Products - Consumables generated 358.23million,slightlyabovetheestimateof358.23 million, slightly above the estimate of 356.72 million, with an 8.7% year-over-year increase [4] - Healthcare Products - Capital equipment revenues were 254.80million,belowtheestimated254.80 million, below the estimated 285.02 million, showing a decline of 4.5% year-over-year [4] - Healthcare Products - Service revenues reached 363.01million,exceedingtheestimateof363.01 million, exceeding the estimate of 341.91 million, with a year-over-year increase of 13.5% [4] - Life Sciences revenues totaled 136.38million,belowtheestimateof136.38 million, below the estimate of 141.59 million, marking a 7% decline year-over-year [4] - Applied Sterilization Technologies (AST) revenues were 258.14million,slightlyabovetheestimateof258.14 million, slightly above the estimate of 254.63 million, with a year-over-year increase of 9.9% [4] - Life Sciences - Service revenues were 36.64million,belowtheestimateof36.64 million, below the estimate of 41.15 million, reflecting a 12% decline year-over-year [4] - Life Sciences - Capital equipment revenues were 31.06million,exceedingtheestimateof31.06 million, exceeding the estimate of 28.74 million, but showing a significant decline of 30.7% year-over-year [4] - Life Sciences - Consumables revenues were 68.68million,belowtheestimateof68.68 million, below the estimate of 78.26 million, with a year-over-year increase of 14.3% [4] Operating Income - Operating income for Healthcare was 246.92million,surpassingtheaverageestimateof246.92 million, surpassing the average estimate of 231.39 million [4] - Corporate and Other reported an operating loss of 100.84million,worsethantheaverageestimateof100.84 million, worse than the average estimate of -86.36 million [4] - Operating income for Applied Sterilization Technologies (AST) was 115.76million,slightlyabovetheestimateof115.76 million, slightly above the estimate of 112.21 million [4] Stock Performance - Steris shares have returned +6.3% over the past month, outperforming the Zacks S&P 500 composite's +1.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]